Swift, B. http://orcid.org/0000-0002-1411-2973
Naci, H. http://orcid.org/0000-0002-7192-5751
Taneri, B.
Becker, C. M. http://orcid.org/0000-0002-9870-9581
Zondervan, K. T. http://orcid.org/0000-0002-0275-9905
Rahmioglu, N. http://orcid.org/0000-0002-5169-8571
Article History
Accepted: 27 January 2022
First Online: 14 February 2022
Declarations
:
: CMB declares that he is part of a scientific collaboration between Oxford University and Bayer Healthcare Ltd. for the purpose of drug target identification in endometriosis. He holds/has held research grants from Bayer Healthcare, Volition Rx, MDNA Life Sciences and Roche Diagnostics and has in recent years been a consultant for Abbvie Inc. and Roche Diagnostics. KTZ declares that she has scientific collaborations outside the submitted work with Bayer Healthcare, MDNA Life Sciences, Roche Diagnostics Inc., and Volition Rx and is a Board member (Secretary) of the World Endometriosis Society, Research Advisory Board member of Wellbeing of Women, UK (research charity) and Chair of the Research Directions Working Group, World Endometriosis Society. NR declares that she is the founding president of Cyprus Women’s Health Research Society in Northern Cyprus.
: Two ethics approvals were obtained for the study: (1) International ethics approval from the Oxford Tropical Research Ethics Committee (OxTREC) of the University of Oxford (OxTREC reference: 37–17) and (2) Local ethics approval from the Eastern Mediterranean University Ethics Committee (ETK00-2017-0240).
: After the participant had been informed about the study and made the decision to take part, a written consent was obtained.
: Not applicable.